William J Towner

Summary

Affiliation: Kaiser Permanente
Country: USA

Publications

  1. ncbi The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction
    William J Towner
    Department of Internal Medicine, Division of Infectious Diseases, Kaiser Permanente, Los Angeles, CA 90027, USA
    J Acquir Immune Defic Syndr 60:321-7. 2012
  2. ncbi Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study
    William Towner
    Department of Internal Medicine, Kaiser Permanente, Los Angeles, CA 90027, USA
    J Acquir Immune Defic Syndr 51:367-73. 2009
  3. ncbi Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States
    William Towner
    Kaiser Permanente Infectious Diseases, Los Angeles, CA 90027, USA
    J Acquir Immune Defic Syndr 53:614-8. 2010
  4. ncbi Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance
    William J Towner
    Kaiser Permanente, Los Angeles, CA, USA
    Antivir Ther 15:803-16. 2010
  5. ncbi Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons
    Chun Chao
    Kaiser Permanente Southern California, Pasadena, CA, USA
    AIDS 26:2223-31. 2012
  6. ncbi Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence
    Michael A Horberg
    Mid Atlantic Permanente Research Institute, Rockville, MD 20852, USA
    J Acquir Immune Defic Syndr 60:183-90. 2012

Collaborators

Detail Information

Publications6

  1. ncbi The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction
    William J Towner
    Department of Internal Medicine, Division of Infectious Diseases, Kaiser Permanente, Los Angeles, CA 90027, USA
    J Acquir Immune Defic Syndr 60:321-7. 2012
    ..Limited data exists regarding the effect of chronic HIV infection on the liver. We sought to characterize the hepatic risks of HIV infection, immunodeficiency, and cumulative use of antiretroviral therapy (ART)...
  2. ncbi Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study
    William Towner
    Department of Internal Medicine, Kaiser Permanente, Los Angeles, CA 90027, USA
    J Acquir Immune Defic Syndr 51:367-73. 2009
    ..To determine the safety and efficacy of changing enfuvirtide to raltegravir in HIV-1-infected patients with HIV-1 RNA below the level of quantification for at least 6 months on an enfuvirtide-containing antiretroviral regimen...
  3. ncbi Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States
    William Towner
    Kaiser Permanente Infectious Diseases, Los Angeles, CA 90027, USA
    J Acquir Immune Defic Syndr 53:614-8. 2010
    ..Etravirine, a nonnucleoside reverse transcriptase inhibitor, was provided through an international early access program (EAP) prior to regulatory approval...
  4. ncbi Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance
    William J Towner
    Kaiser Permanente, Los Angeles, CA, USA
    Antivir Ther 15:803-16. 2010
    ..This review examines the clinical development and drug profile of etravirine, placing it in the context of other antiretrovirals available for treatment-experienced patients...
  5. ncbi Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons
    Chun Chao
    Kaiser Permanente Southern California, Pasadena, CA, USA
    AIDS 26:2223-31. 2012
    ..Studies are needed to directly evaluate the effect of ART use on cancer risk...
  6. ncbi Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence
    Michael A Horberg
    Mid Atlantic Permanente Research Institute, Rockville, MD 20852, USA
    J Acquir Immune Defic Syndr 60:183-90. 2012
    ..We seek to determine the optimized multidisciplinary care team (MDCT) composition for antiretroviral therapy (ART) adherence...